Speeding tumor genotyping during the SARS‐CoV‐2 outbreak through liquid biopsy

Rolfo, Christian; Russo, Alessandro; Pérez, Diego

doi:10.1002/cncr.32983

Cited by 9 publications

(8 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Therefore, it is important to consider NSCLC patients as a specific population to be priority tested due to the increased risk of complications caused by older age, significant cardiovascular and respiratory comorbidities and smoking-related lung damage. In this pandemic scenario, the use of liquid biopsy might be implemented in order to reduce the risks of COVID-19 infection for NSCLC patients by limiting their access to the oncology departments (Rolfo et al, 2020) The proposed diagnostic approach might be practice changing even in the upcoming months when COVID-19 outbreak will be under control.…”

Section: Discussionmentioning

confidence: 99%

Italian survey on the clinical management of non-small cell lung cancer patients during the COVID-19 pandemic: A lesson for the second wave

Bertaglia

Reale

Bironzo

et al. 2021

Critical Reviews in Oncology/Hematology

View full text Add to dashboard Cite

This study investigated the clinical management of non small cell lung cancer (NSCLC) patients during the first wave of coronavirus disease 2019 (COVID-19) outbreak in Italy. A 29-questions survey was sent to 95 Italian thoracic oncologists, with 77 % of them declaring significant changes in the outpatients management and treatment. The results of this survey pointed out a significant delay of lung cancer diagnosis along with a relevant reduction of patients' accrual within clinical trials. Telemedicine emerged as a valid support for patienthealthcare interactions. Therapeutic indications followed the guidelines for adjuvant chemotherapy and concurrent chemo-radiation. Clinical indications to first-line therapies were largely confirmed, while major changes regarded the selection of second line treatment options as well as the management of elderly population.This work may represent a valid source of information to improve the clinical management of NSCLC patients during second wave of COVID-19 pandemic.

show abstract

Section: Discussionmentioning

confidence: 99%

Italian survey on the clinical management of non-small cell lung cancer patients during the COVID-19 pandemic: A lesson for the second wave

Bertaglia

Reale

Bironzo

et al. 2021

Critical Reviews in Oncology/Hematology

View full text Add to dashboard Cite

show abstract

“…It could also help cytopathologists overcome some of the shortcomings associated with tissue biopsies, including the unavailability of tissue specimens for molecular purposes. Further, it could minimize the risk of handling potentially infectious airway tissue samples, thereby avoiding a potential spread of the virus among staff ( 58 ). Besides these advantages, recent research has also fully validated the efficiency of this approach in detecting cancer driver mutations both in early and in late stage lung cancer patients.…”

Section: Liquid Biopsy: Pre-analytical and Analytical Issuesmentioning

confidence: 99%

“…Plausibly, the lower volume of processed liquid biopsy samples was ascribable, on one hand, to patients’ reluctance to visit hospitals for fear of contracting the virus, and, on the other hand, to the drop in scheduled hospital appointments to ensure social distancing. Intriguingly, to circumvent this limitation, Rolfo et al recently proposed a shift in the current diagnostic workflow of liquid biopsy samples, emphasizing the need of implementing home phlebotomy services and/or mobile units for blood draws and transport, followed by a central NGS analysis of ctDNA ( 58 ). Finally, this new approach could also be applied to monitor the efficacy of systemic treatments, including targeted drugs, and to modify the way clinical trials are carried out, especially during the current pandemic ( 58 ).…”

Section: Liquid Biopsy: Pre-analytical and Analytical Issuesmentioning

confidence: 99%

“…Intriguingly, to circumvent this limitation, Rolfo et al recently proposed a shift in the current diagnostic workflow of liquid biopsy samples, emphasizing the need of implementing home phlebotomy services and/or mobile units for blood draws and transport, followed by a central NGS analysis of ctDNA ( 58 ). Finally, this new approach could also be applied to monitor the efficacy of systemic treatments, including targeted drugs, and to modify the way clinical trials are carried out, especially during the current pandemic ( 58 ).…”

Section: Liquid Biopsy: Pre-analytical and Analytical Issuesmentioning

confidence: 99%

See 1 more Smart Citation

A narrative review on the implementation of liquid biopsy as a diagnostic tool in thoracic tumors during the COVID-19 pandemic

Pisapia¹,

Pepe²,

Gristina³

et al. 2021

Mediastinum

View full text Add to dashboard Cite

Objective In this review, we evaluate the role of liquid biopsy in managing lung cancer patients during the still ongoing coronavirus disease 2019 (COVID-19) healthcare emergency. Background The novel influenza coronavirus (severe acute respiratory syndrome coronavirus or SARS-CoV-2) has upended several aspects of our lives, including medical activities. In this setting, many routine cancer diagnostic and therapeutic procedures have been suspended, leading to delays in diagnosis, treatments, and, ultimately, increases in cancer mortality rates. Equally drastic has been the impact of COVID-19 on clinical trials, many of which have been stalled or have never begun. This has left many patients who were hoping to receive innovative treatments in a limbo. Although, as of today, the introduction of drastic security measures has been crucially important to contain the pandemic, one cannot ignore the need to continue providing chronically ill patients all the health care they need, in terms of detection, prevention, and treatment. In these unprecedented times, liquid biopsy, more than ever before, may play a relevant role in the adequate management of these frail patients. Methods we performed a deep analysis of the recent international literature published in English on PUBMED in the last six months focused on the impact of SARS-CoV-2 on the management of lung cancer patients, focusing the attention on the role of liquid biopsy. Conclusions COVID-19 pandemic has significantly modified our lives and overall medical practice. In these unprecedented times, liquid biopsy may represent a valid and less time-consuming diagnostic approach than conventional tissue and cytological specimens.

show abstract

“…LB can be employed to monitor the course of the disease and treatment choices, including the detection of circulating cancer cells, nucleic acids, proteins and other markers. In the last years, as a matter of fact, LB has proved to be a promising minimally invasive diagnostic tool, and it could be a great help in the current COVID-19 pandemic situation, in which cancer patients’ management and follow-up could be challenging [3] . Moreover, thanks to the low volumes of sample usually needed for analysis (few microliters), LB could represent a valid alternative to identify biomarkers of pathologies and repeated analysis are not heavy to bear from patients’ point of view.…”

Section: Introductionmentioning

confidence: 99%